Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03552406
• Other study ID #: ISU104-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 27, 2018
• Est. completion date: December 31, 2021

Study information

• Verified date: May 2021
• Source: ISU Abxis Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase I, open-label, dose-finding study to assess the safety, tolerability and pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with advanced solid tumors.

Description:

[Part 1 Dose-escalation] This study ams to evaluate the safety, tolerability, and pharmacokinetics of ISU104 in patients with advanced solid tumors. Primary objective To determine recommended Phase II dose (RP2D) of ISU104 based on the results of its safety and tolerability in patients with advanced solid tumors. Secondary objectives 1. To evaluate pharmacokinetics (PK) of ISU104 in patients with advanced solid tumors. 2. To evaluate efficacy of ISU104 in patients with advanced solid tumors. Exploratory purpose To identify the expression of explorable multiple tumor biomarkers and to analyze the relationship between biomarkers and antitumor activity of ISU104. [Part 2 dose-expansion] The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 alone or ISU104 in combination with cetuximab. Primary objective To determine RP2D of ISU104 based on results of its safety and tolerability in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. Secondary objectives 1. To evaluate the pharmacokinetics of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. 2. To evaluate the efficacy of ISU104 in patients with recurrent/metastatic HNSCC (except for nasopharyngeal cancer), when administered intravenously ISU104 only or ISU104 in combination with cetuximab. Exploratory purpose To explore a variety of detectable tumor biomarkers and evaluate the relationship between these biomarkers and antitumor activity of ISU104.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 33
• Est. completion date: December 31, 2021
• Est. primary completion date: October 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

Common

1. Male or Female with = 19 years of age

2. Histologically or Cytologically confirmed a diagnosis of an advanced solid tumor that was refractory to standard treatment or for which no standard therapy existed, or patients declined any treatment options

3. Eastern Cooperative Oncology Group (ECOG) performance status = 2

4. Life Expectancy = 12 weeks

5. Adequate Hematological, Renal and Hepatic function

6. According to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1, the patient had at least one measurable lesion

Exclusion Criteria:

1. Severe hypersensitivity or a history of any hypersensitivity to the similar drug class of IP

2. Patients underwent the major surgery or procedure, or had the medical history (as

blow):

• Major surgery requiring systemic anesthesia or respiratory assist device within 4 weeks prior to baseline [2 weeks in case of video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery)]
• Severe cardiovascular disease within 24 weeks prior to baseline
• Severe cerebrovascular disease within 24 weeks prior to baseline
• Pulmonary thromboembolism, deep vein thrombosis (DVT) or other clinically and significantly severe lung disease within 24 weeks prior to baseline

3. Patients had the following concurrent diseases at baseline:

• Hematologic malignancies including lymphoma
• Clinically significant symptom or uncontrolled central nervous system (CNS) or brain metastases
• Pleural effusion and ascites drainage
• Uncontrolled hypertension (SBP/DBP > 160/100 mmHg)
• Active hepatitis B or C virus
• Human immunodeficiency virus (HIV) that is positive
• Thromboembolic disease or bleeding diatheses
• Interstitial lung disease (ILD)

4. Left ventricular ejection fraction (LVEF) value, when measured by echocardiogram, multiple gated acquisition (MUGA) scan or a standard procedure in the institution within 4 weeks prior to the study entry

5. Patients with the following medication history:

• anti-ErbB3 targeted therapies
• small-molecule tyrosine kinase inhibitors within 2 weeks prior to baseline
• any anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for the treatment of advanced solid tumors within 4 weeks prior to baseline
• Granulocyte-Colony Stimulating Factor (G-CSF), packed red cell or platelet transfusion within 2 weeks prior to the first injection of IP to correct the abnormal values of absolute neutrophil count (ANC) or platelet count

6. Pregnant woman, breastfeeding woman, or women of childbearing age and men with partners of childbearing age, unless they are willing to follow abstinence or use effective forms of contraception* from the study entry until at least 16 weeks after the EOT visit

7. Subjects receiving any other investigational products or medical devices within 4 weeks prior to screening

8. Principal investigator's opinion [Part 1 Dose-escalation cohort]

1. Patients with severe hypersensitivity or history of hypersensitivity to the similar drug class of the investigational product.

2. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for treatment of advanced solid tumors within four weeks prior to baseline. [Part 2 dose-expansion cohort]

1. Patients with history of allergy or hypersensitivity to the investigational product (ISU104 or cetuximab) or any excipients of the investigational product or its similar derivatives.

2. Patients with primary malignant neoplasm, including head and neck cancer as specified in inclusion criteria of Part 2 dose-expansion cohort. However, an exception may be

allowed for the following:

• For respective malignancy, treatment-naïve or disease-free patients for at least three years (however, patients undergoing radical resection on papillary thyroid carcinoma may be eligible for this clinical trial, even though three years have not passed).
• Total dissection of skin basal cell carcinoma/squamous cell carcinoma or at least one year had passed since successful treatment of cervical intraepithelial neoplasia.

3. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, therapeutic/palliative radiotherapy, or hormone therapy for treatment of advanced solid tumors within four weeks prior to baseline.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Biological:
• ISU104
Intravenous Infusion for 1 hour.

Drug:
• Cetuximab
Intravenous Infusion for 1 hour (2 hours at initial dose)

Locations

Country	Name	City	State
Korea, Republic of	Kosin University Gospel Hospital	Busan
Korea, Republic of	Kyungpook National University Chilgok Hospital	Daegu
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
ISU Abxis Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities	Determination of MTD is dependent upon number of cohorts and patients required	From date of first dose to 4 weeks after administration.
Secondary	Toxicity Evaluation	To determine the occurrence of Adverse Events (AEs)	through the study completion, an average of 1 year
Secondary	Determine Immunogenicity of ISU104	To measure the level of Anti-Drug Antibody (ADA) and/or Neutralizing Antibody (NAb) of ISU104	through the study completion, an average of 1 year
Secondary	Determine the Peak Plasma Concentration (Cmax) of ISU104	To measure the Peak Plasma Concentration (Cmax) of ISU104	up to 12 weeks
Secondary	Determine the Area Under the Curve (AUC) of ISU104	To measure the Area under the plasma concentration versus time curve (AUC) of ISU104	up to 12 weeks
Secondary	Explore Overall Response Rate (ORR) of ISU104 or ISU104+Cetuximab	To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as >30% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline	up to progression, an average 6 months
Secondary	Explore Disease Control Rate (DCR) of ISU104 or ISU104+Cetuximab	To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as >30% decrease in tumor burden from baseline, a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline, and Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Partial Response (defined as >20% decrease in tumor burden from baseline)	up to progression, an average 6 months
Secondary	Explore Progression-Free Survival (PFS) of ISU104 or ISU104+Cetuximab	To measure the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse	up to progression, an average 6 months